Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma.

Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP.

Pediatrics. 2019 Jun;143(6). pii: e20182495. doi: 10.1542/peds.2018-2495. Epub 2019 May 14.

PMID:
31088894
2.

Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro.

Samy RN, Lipschitz N, Earl BR, Cripe TP.

Otolaryngol Head Neck Surg. 2019 May;160(5):891-893. doi: 10.1177/0194599818821863. Epub 2019 Jan 1.

PMID:
30598045
3.

Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.

Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP.

Mol Ther Oncolytics. 2018 Oct 18;11:62-74. doi: 10.1016/j.omto.2018.10.001. eCollection 2018 Dec 21.

4.

Please stand by: how oncolytic viruses impact bystander cells.

Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP.

Future Virol. 2018 Sep;13(9):671-680. doi: 10.2217/fvl-2018-0068. Epub 2018 Aug 8. Review.

PMID:
30416535
5.

Oncolytic virus and PD-1/PD-L1 blockade combination therapy.

Chen CY, Hutzen B, Wedekind MF, Cripe TP.

Oncolytic Virother. 2018 Jul 31;7:65-77. doi: 10.2147/OV.S145532. eCollection 2018. Review.

6.

Advances in the diagnosis and management of cardiomyopathy in Duchenne muscular dystrophy.

Hor KN, Mah ML, Johnston P, Cripe TP, Cripe LH.

Neuromuscul Disord. 2018 Sep;28(9):711-716. doi: 10.1016/j.nmd.2018.06.014. Epub 2018 Jul 6. Review.

PMID:
30064893
7.

After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine?

Cripe TP.

Acad Med. 2018 Aug;93(8):1099-1100. doi: 10.1097/ACM.0000000000002277. No abstract available.

PMID:
30044274
8.

Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens.

Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP.

Pediatr Blood Cancer. 2018 Nov;65(11):e27313. doi: 10.1002/pbc.27313. Epub 2018 Jul 17.

PMID:
30015384
9.

Pediatric Cancer Immunotherapy: Opportunities and Challenges.

Wedekind MF, Denton NL, Chen CY, Cripe TP.

Paediatr Drugs. 2018 Oct;20(5):395-408. doi: 10.1007/s40272-018-0297-x. Review.

10.

Immunotherapy for osteosarcoma: Where do we go from here?

Wedekind MF, Wagner LM, Cripe TP.

Pediatr Blood Cancer. 2018 Sep;65(9):e27227. doi: 10.1002/pbc.27227. Epub 2018 Jun 19. Review.

PMID:
29923370
11.

A multiyear quality improvement project to increase influenza vaccination in a pediatric oncology population undergoing active therapy.

Olshefski RS, Bibart M, Frost R, Wood E, Hampl J, Mangum R, Ardura M, Guinipero T, Cripe TP.

Pediatr Blood Cancer. 2018 Sep;65(9):e27268. doi: 10.1002/pbc.27268. Epub 2018 Jun 1.

PMID:
29856533
12.

Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles.

Fu X, Tao L, Wang PY, Cripe TP, Zhang X.

Oncotarget. 2018 Apr 20;9(30):21348-21358. doi: 10.18632/oncotarget.25096. eCollection 2018 Apr 20.

13.

Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA.

Franson T, Kinnett K, Cripe TP.

Ther Innov Regul Sci. 2019 Jan;53(1):154-163. doi: 10.1177/2168479018764650. Epub 2018 Mar 25.

PMID:
29714576
14.

High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.

Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP.

Viruses. 2018 Mar 15;10(3). pii: E132. doi: 10.3390/v10030132.

15.

Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.

Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP.

Oncotarget. 2017 May 30;8(47):82037-82048. doi: 10.18632/oncotarget.18301. eCollection 2017 Oct 10.

16.

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma.

Hutzen B, Chen CY, Wang PY, Sprague L, Swain HM, Love J, Conner J, Boon L, Cripe TP.

Mol Ther Oncolytics. 2017 Sep 8;7:17-26. doi: 10.1016/j.omto.2017.09.001. eCollection 2017 Dec 15.

17.

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.

Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K.

Cancer Res. 2017 Nov 1;77(21):5706-5711. doi: 10.1158/0008-5472.CAN-17-1789. Epub 2017 Oct 9. Review.

18.

The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells.

Dai HS, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, Suenaga T, Arase H, Nakano I, Chiocca EA, Kaur B, Yu J, Caligiuri MA.

Immunity. 2017 Jul 18;47(1):159-170.e10. doi: 10.1016/j.immuni.2017.06.019.

19.

Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors.

Studebaker AW, Hutzen BJ, Pierson CR, Haworth KB, Cripe TP, Jackson EM, Leonard JR.

Mol Ther Oncolytics. 2017 May 25;6:22-30. doi: 10.1016/j.omto.2017.05.005. eCollection 2017 Sep 15.

20.

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models.

Chen CY, Wang PY, Hutzen B, Sprague L, Swain HM, Love JK, Stanek JR, Boon L, Conner J, Cripe TP.

Sci Rep. 2017 May 24;7(1):2396. doi: 10.1038/s41598-017-02503-8.

21.

Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?

Denton NL, Chen CY, Scott TR, Cripe TP.

Biomedicines. 2016 Jul 7;4(3). pii: E13. doi: 10.3390/biomedicines4030013. Review.

22.

Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.

Currier MA, Stehn JR, Swain A, Chen D, Hook J, Eiffe E, Heaton A, Brown D, Nartker BA, Eaves DW, Kloss N, Treutlein H, Zeng J, Alieva IB, Dugina VB, Hardeman EC, Gunning PW, Cripe TP.

Mol Cancer Ther. 2017 Aug;16(8):1555-1565. doi: 10.1158/1535-7163.MCT-16-0873. Epub 2017 May 18.

23.

Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients.

Streby KA, Geller JI, Currier MA, Warren PS, Racadio JM, Towbin AJ, Vaughan MR, Triplet M, Ott-Napier K, Dishman DJ, Backus LR, Stockman B, Brunner M, Simpson K, Spavin R, Conner J, Cripe TP.

Clin Cancer Res. 2017 Jul 15;23(14):3566-3574. doi: 10.1158/1078-0432.CCR-16-2900. Epub 2017 May 11.

24.

Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS.

Cancer. 2017 Jun 15;123(12):2368-2375. doi: 10.1002/cncr.30613. Epub 2017 Feb 17.

25.

Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.

Currier MA, Sprague L, Rizvi TA, Nartker B, Chen CY, Wang PY, Hutzen BJ, Franczek MR, Patel AV, Chaney KE, Streby KA, Ecsedy JA, Conner J, Ratner N, Cripe TP.

Oncotarget. 2017 Mar 14;8(11):17412-17427. doi: 10.18632/oncotarget.14885.

26.

Pediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases.

Thompson JC, Woods GM, Arnold MA, Elmaraghy C, Kahwash SB, Cripe TP, Setty BA.

Case Rep Oncol. 2016 Aug 17;9(2):447-453. eCollection 2016 May-Aug.

27.

Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.

Orienti I, Falconi M, Teti G, Currier MA, Wang J, Phelps M, Cripe TP.

Pharm Res. 2016 Nov;33(11):2722-35. doi: 10.1007/s11095-016-1999-9. Epub 2016 Jul 25.

28.

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.

Cassady KA, Haworth KB, Jackson J, Markert JM, Cripe TP.

Viruses. 2016 Feb 4;8(2). pii: E43. doi: 10.3390/v8020043. Review.

29.

Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility.

Wang PY, Swain HM, Kunkler AL, Chen CY, Hutzen BJ, Arnold MA, Streby KA, Collins MH, Dipasquale B, Stanek JR, Conner J, van Kuppevelt TH, Glorioso JC, Grandi P, Cripe TP.

Gene Ther. 2016 Feb;23(2):135-43. doi: 10.1038/gt.2015.105. Epub 2015 Nov 19.

30.

Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.

Haworth KB, Arnold MA, Pierson CR, Leddon JL, Kurmashev DK, Swain HM, Hutzen BJ, Roberts RD, Cripe TP.

Pediatr Blood Cancer. 2016 Apr;63(4):618-26. doi: 10.1002/pbc.25842. Epub 2015 Nov 17.

PMID:
26575538
31.

Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.

Nakashima H, Kaufmann JK, Wang PY, Nguyen T, Speranza MC, Kasai K, Okemoto K, Otsuki A, Nakano I, Fernandez S, Goins WF, Grandi P, Glorioso JC, Lawler S, Cripe TP, Chiocca EA.

J Clin Invest. 2015 Nov 2;125(11):4269-80. doi: 10.1172/JCI80713. Epub 2015 Oct 20.

32.

Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.

Cripe TP, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Markert JM, Waters AM, Gillespie GY, Beierle EA, Friedman GK.

Mol Ther Oncolytics. 2015;2. pii: 15015. Epub 2015 Sep 16.

33.

Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children.

Friedman GK, Beierle EA, Gillespie GY, Markert JM, Waters AM, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Cripe TP.

Mol Ther Oncolytics. 2015;2. pii: 15016. Epub 2015 Sep 16.

34.

Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Jousma E, Rizvi TA, Wu J, Janhofer D, Dombi E, Dunn RS, Kim MO, Masters AR, Jones DR, Cripe TP, Ratner N.

Pediatr Blood Cancer. 2015 Oct;62(10):1709-16. doi: 10.1002/pbc.25546. Epub 2015 Apr 22.

35.

Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma.

Woods GM, Bondra K, Chronowski C, Leasure J, Singh M, Hensley L, Cripe TP, Chakravarti A, Houghton P.

Pediatr Blood Cancer. 2015 Sep;62(9):1550-1554. doi: 10.1002/pbc.25516. Epub 2015 Mar 19.

36.

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.

Leddon JL, Chen CY, Currier MA, Wang PY, Jung FA, Denton NL, Cripe KM, Haworth KB, Arnold MA, Gross AC, Eubank TD, Goins WF, Glorioso JC, Cohen JB, Grandi P, Hildeman DA, Cripe TP.

Mol Ther Oncolytics. 2015 Jan 21;1:14010. doi: 10.1038/mto.2014.10. eCollection 2015.

37.

Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ.

Mol Ther. 2015 Mar;23(3):602-8. doi: 10.1038/mt.2014.243. Epub 2014 Dec 22.

38.

Going back to class I: MHC and immunotherapies for childhood cancer.

Haworth KB, Leddon JL, Chen CY, Horwitz EM, Mackall CL, Cripe TP.

Pediatr Blood Cancer. 2015 Apr;62(4):571-6. doi: 10.1002/pbc.25359. Epub 2014 Dec 18. Review.

39.

Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.

Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM.

Pediatr Blood Cancer. 2015 May;62(5):743-50. doi: 10.1002/pbc.25269. Epub 2014 Oct 12.

40.

Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Bolyard C, Yoo JY, Wang PY, Saini U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur B.

Clin Cancer Res. 2014 Dec 15;20(24):6479-94. doi: 10.1158/1078-0432.CCR-14-0463. Epub 2014 Oct 7.

41.

Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS.

J Clin Oncol. 2014 Nov 1;32(31):3547-52. doi: 10.1200/JCO.2014.55.6787. Epub 2014 Sep 29.

42.

Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.

Streby KA, Shah N, Ranalli MA, Kunkler A, Cripe TP.

Pediatr Blood Cancer. 2015 Jan;62(1):5-11. doi: 10.1002/pbc.25200. Epub 2014 Aug 30. Review.

43.

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, Kaur B.

Clin Cancer Res. 2014 Jul 15;20(14):3787-98. doi: 10.1158/1078-0432.CCR-14-0553. Epub 2014 May 9.

44.

Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.

Wagner LM, Yin H, Eaves D, Currier M, Cripe TP.

Pediatr Blood Cancer. 2014 Nov;61(11):2096-8. doi: 10.1002/pbc.25062. Epub 2014 Apr 19.

PMID:
24753077
45.

MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.

Brundage ME, Tandon P, Eaves DW, Williams JP, Miller SJ, Hennigan RH, Jegga A, Cripe TP, Ratner N.

Oncogene. 2014 Dec 4;33(49):5626-36. doi: 10.1038/onc.2013.506. Epub 2014 Feb 10.

46.

A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells.

Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, Zeng J, Nascimento PR, Sequeira VB, Butler TL, Allanson M, Fath T, Hill TA, McCluskey A, Schevzov G, Palmer SJ, Hardeman EC, Winlaw D, Reeve VE, Dixon I, Weninger W, Cripe TP, Gunning PW.

Cancer Res. 2013 Aug 15;73(16):5169-82. doi: 10.1158/0008-5472.CAN-12-4501. Erratum in: Cancer Res. 2013 Oct 1;73(19):6094.

47.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.

Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12.

48.

EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.

Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner N.

Oncogene. 2014 Jan 9;33(2):173-80. doi: 10.1038/onc.2012.579. Epub 2013 Jan 14.

49.

Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV.

Wang PY, Currier MA, Hansford L, Kaplan D, Chiocca EA, Uchida H, Goins WF, Cohen JB, Glorioso JC, van Kuppevelt TH, Mo X, Cripe TP.

Gene Ther. 2013 Jul;20(7):761-9. doi: 10.1038/gt.2012.93. Epub 2012 Dec 20.

50.

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N.

J Clin Invest. 2013 Jan;123(1):340-7. doi: 10.1172/JCI60578. Epub 2012 Dec 10.

Supplemental Content

Loading ...
Support Center